Breast cancer recurrent

6 clinical trials

Quick filters

Clinical trials for Breast cancer recurrent

6 trials across Europe

See all trials →

Quick filters

6 Clinical trials

Endometrial cancer+38

Recruiting

InvestigationalNo placebo

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Ds-3939A
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Breast cancer stage III+2

Not recruiting

Registered drugNo placebo

Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ceralasertib
Sponsor:Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets

Contact Research Centre

Breast cancer+7

Not recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:GBG Forschungs GmbH

Contact Research Centre

Hormone receptor positive breast cancer+2

Not recruiting

Registered drugNo placebo

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Palbociclib
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Carboplatin
Sponsor:Institut Jules Bordet

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

Registered drugNo placebo

Hungary

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Daehwa Pharmaceutical Co. Ltd.

Contact Research Centre

See all trials →

Breast cancer recurrent

Clinical trials for Breast cancer recurrent

Endometrial cancer+38

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

Breast cancer stage III+2

Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound

Breast cancer+7

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Hormone receptor positive breast cancer+2

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Breast cancer metastatic+2

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Breast cancer metastatic+2

Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.